Login to Your Account

TopoTarget Stock Surges on Trickle of Data for Belinostat

By Cormac Sheridan
Staff Writer

Tuesday, March 5, 2013
Without revealing much in the way of new data, TopoTarget A/S enjoyed a 45 percent bounce in its share price in early trading Tuesday, as an analysis of the final top-line results from a registration trial of belinostat in patients with relapsed or refractory peripheral T-cell lymphoma confirmed the drug exceeded the efficacy level defined by the study's primary endpoint.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription